Imunon, Inc. (IMNN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Imunon, Inc. (IMNN) Healthcare & Pipeline Overview

Imunon, Inc. is a clinical-stage biotechnology company specializing in DNA-based immunotherapies, vaccines, and directed chemotherapies. Their focus on novel cancer treatments, including GEN-1 and ThermoDox, positions them within the competitive biotechnology landscape, targeting unmet needs in oncology.

What Is the Investment Thesis for IMNN?

Imunon, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is significantly influenced by the clinical progress of GEN-1 and ThermoDox. Positive Phase 2 data for GEN-1 in ovarian cancer could serve as a major catalyst, potentially leading to partnerships or further investment. ThermoDox's development for multiple cancer indications also offers upside potential, though clinical trial outcomes remain a key risk. The company's success hinges on navigating regulatory hurdles and securing funding to advance its pipeline. Investors should closely monitor clinical trial results, partnership announcements, and financial runway to assess the investment viability.

Based on FMP financials and quantitative analysis

IMNN Key Highlights

Imunon's lead product, GEN-1, is a DNA-based immunotherapy targeting localized treatment of ovarian cancer.

• ThermoDox, a heat-activated liposomal doxorubicin, is in development for various cancer indications.
• The company has two feasibility stage platform technologies for nucleic acid-based therapies.
• Imunon changed its name from Celsion Corporation in September 2022.
• The company is based in Lawrenceville, New Jersey, and employs 25 people.

Who Are IMNN's Competitors?

IMNN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMNN's Key Strengths?

Proprietary DNA-based immunotherapy platform.

• Clinical-stage product pipeline with GEN-1 and ThermoDox.
• Experienced management team with expertise in oncology.
• Potential for targeted cancer treatment with localized therapies.

What Are IMNN's Weaknesses?

Limited financial resources and reliance on external funding.

• High risk associated with clinical-stage drug development.
• Dependence on successful clinical trial outcomes.
• Small team size limits bandwidth for multiple projects.

What Could Drive IMNN Stock Higher?

GEN-1 Phase 2 clinical trial data readout in ovarian cancer.

• ThermoDox clinical trial initiation in a new cancer indication.
• Potential for strategic partnership or licensing agreement.
• Progress in platform technology development for new immunotherapies.

What Are the Key Risks for IMNN?

Financial-distress signal — its Altman Z-Score of -42.59 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or denial of approval.
• Competition from established pharmaceutical companies.
• Difficulty in securing funding for research and development.
• Patent challenges or intellectual property disputes.

What Are the Growth Opportunities for IMNN?

• GEN-1 Clinical Advancement: The continued clinical development of GEN-1 for the treatment of ovarian cancer represents a significant growth opportunity for Imunon. Positive results from ongoing or future clinical trials could lead to accelerated regulatory approval and commercialization. The market for ovarian cancer treatments is substantial, with a global market size estimated at billions of dollars annually. Successful commercialization of GEN-1 could generate significant revenue for Imunon, establishing it as a key player in the ovarian cancer treatment landscape. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
• ThermoDox Expansion: Imunon's ThermoDox has the potential to be expanded into multiple cancer indications beyond its current development focus. By exploring ThermoDox's efficacy in other solid tumors, Imunon can broaden its market reach and diversify its revenue streams. The global market for cancer therapeutics is vast, with specific segments like liver cancer and breast cancer representing multi-billion dollar opportunities. Successful expansion of ThermoDox into these areas could significantly increase Imunon's market capitalization. Timeline: Clinical trials in new indications could commence within the next 2-3 years.
• Platform Technology Development: Imunon's two feasibility stage platform technologies for nucleic acid-based immunotherapies offer a long-term growth opportunity. These platforms could lead to the development of new vaccines and anti-cancer therapies, providing a pipeline of future products. The market for nucleic acid-based therapies is rapidly growing, driven by advancements in gene editing and personalized medicine. Successful development of these platforms could position Imunon as a leader in this emerging field. Timeline: Initial product candidates from these platforms could enter preclinical development within the next 3-5 years.
• Strategic Partnerships: Imunon can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships can provide access to funding, expertise, and established distribution networks. The biotechnology industry is characterized by collaborations between smaller innovative companies and larger pharmaceutical firms. Securing a partnership with a major player could validate Imunon's technology and significantly enhance its market prospects. Timeline: Partnership opportunities could materialize within the next 1-2 years, contingent on clinical trial progress.
• Orphan Drug Designation: Seeking orphan drug designation for GEN-1 in ovarian cancer could provide Imunon with regulatory and commercial advantages. Orphan drug designation can lead to market exclusivity, tax credits, and reduced regulatory fees. The orphan drug market is attractive for biotechnology companies, as it allows them to focus on niche indications with unmet medical needs. Obtaining orphan drug designation for GEN-1 could enhance its commercial potential and attract further investment. Timeline: Application for orphan drug designation can be submitted in the near term, with a decision expected within 1 year.

What Are IMNN's Competitive Advantages?

• Proprietary DNA-based immunotherapy technology.
• Heat-activated liposomal drug delivery system (ThermoDox).
• Patent protection for key products and technologies.
• Clinical data supporting the efficacy of GEN-1 and ThermoDox.

What Does IMNN Do?

Imunon, Inc., founded in 1982 and formerly known as Celsion Corporation until September 2022, is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey. The company is dedicated to the development and commercialization of innovative DNA-based immunotherapies, vaccines, and directed chemotherapies for the treatment of cancer. Imunon's lead product candidate is GEN-1, a DNA-based immunotherapy designed for the localized treatment of ovarian cancer. GEN-1 aims to stimulate the patient's immune system to recognize and attack cancer cells within the peritoneal cavity. Another key asset in Imunon's pipeline is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being developed for various cancer indications, leveraging its ability to deliver chemotherapy directly to tumor sites when activated by heat. In addition to these clinical-stage programs, Imunon has two feasibility stage platform technologies focused on the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. These platforms represent the company's commitment to advancing novel approaches in cancer treatment and expanding its therapeutic pipeline. Imunon operates with a team of 25 employees, focusing on research, development, and clinical trials to bring innovative cancer therapies to market.

What Products and Services Does IMNN Offer?

• Develop DNA-based immunotherapies for cancer treatment.
• Create vaccines for various diseases.
• Develop directed chemotherapies to target cancer cells.
• Focus on localized treatment of ovarian cancer with GEN-1.
• Utilize heat-activated liposomal encapsulation of doxorubicin (ThermoDox) for cancer therapy.
• Research and develop nucleic acid-based immunotherapies.
• Advance anti-cancer DNA or RNA therapies.

How Does IMNN Make Money?

• Develop proprietary immunotherapy and chemotherapy products.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales and licensing agreements.

What Industry Does IMNN Operate In?

Imunon, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for cancer immunotherapies is experiencing substantial growth, driven by the increasing prevalence of cancer and the demand for more effective and targeted treatments. Companies like Imunon are focused on developing novel approaches to stimulate the immune system to fight cancer, differentiating themselves through proprietary technologies and targeted therapies. The industry is also marked by strategic collaborations, partnerships, and acquisitions as companies seek to expand their pipelines and market reach. Success in this sector requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.

Who Are IMNN's Key Customers?

• Hospitals and cancer treatment centers.
• Oncologists and other healthcare professionals.
• Patients with cancer, particularly ovarian cancer.
• Potential pharmaceutical partners for licensing or co-development agreements.

Company Profile

Imunon, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lawrenceville, US. The company is led by CEO Stacy R. Lindborg. IMNN has traded publicly since 1999.

How Imunon, Inc. Is Valued

Imunon, Inc. carries a market capitalization of $6.09M, placing it in the micro-cap category. Analyst price targets span from $10.00 to $10.00, with a consensus of $10.00. At the current price of $1.45, that implies approximately 590% upside potential. Relative to its peer group, IMNN's quantitative score of 26/100 is below the peer average of 64/100.

Key Financial Metrics

Return on assets is -98.2%, showing how much profit it generates from its asset base. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -169.4%, the inverse of the P/E and a quick read on earnings relative to price.

Imunon, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -42.59 places it in the distress zone, a signal of elevated financial risk.

Imunon, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 22.5% above estimates on average.

Wall Street analysts project Imunon, Inc. revenue of about $3.9M for fiscal 2026, with EPS near $-2.36. The estimate reflects 4 contributing analysts.

Over the past six months, Imunon, Inc. insiders filed 29 SEC Form 4 transactions — 5 sales and 24 purchases. On net that is roughly 98K shares acquired (about $163K) — insiders putting money in tends to read as conviction.

IMNN Financials

IMNN Latest News

IMNN Analyst Consensus

IMNN MoonshotScore

IMNN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources